Summary
Updated Aug 30, 2026
Sundeep Agrawal is Director of BlossomHill Therapeutics, Inc. (BLSM). 4 SEC Form 4 filings on record going back to 2024, most recently on 10 August 2026.
Recent Transactions
3Every recent SEC Form 4 transaction Sundeep Agrawal has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Sundeep Agrawal files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $10.00M of BLSM open-market activity in the last 12 months
- Carl L. Gordon - $10.00M of BLSM open-market activity in the last 12 months
- Bihua Chen - $5.00M of BLSM open-market activity in the last 12 months
- John P. Schmid - $96K of BLSM open-market activity in the last 12 months
- Vincent Paul Liptak - $75K of BLSM open-market activity in the last 12 months
- Jason A. Keyes - $11K of BLSM open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Sundeep Agrawal?
Sundeep Agrawal is a corporate insider, tracked as Director of BlossomHill Therapeutics, Inc. (BLSM). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Sundeep Agrawal submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Where can I see all of Sundeep Agrawal's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Sundeep Agrawal and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
